Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526057 · ClinicalTrials.gov registry record · Phase 2
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT01526057 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 220 participants.
The verdict
NCT01526057, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
In this study, patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab). During the course of the study, the effects of the drugs will be assessed by sampling the levels of drug in the blood, blood cell counts, and by comparing these levels among the different treatments. Safety, tolerability and immunologic response also will be evaluated throughout.
Interventions
- BIOLOGICAL PF-05280586
- BIOLOGICAL Rituxan
- BIOLOGICAL MabThera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2012-03-20 |
| Est. Completion | 2014-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526057
The ClinicalTrials.gov registry entry for NCT01526057 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-05280586 is the first listed.
NCT01526057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01526057 about?
NCT01526057 is a clinical study titled "A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)". In this study, patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab). During the course of the study, the effects of the drugs will be assessed by samp...
What is the current status of trial NCT01526057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2012-03-20. Estimated completion is 2014-05-07.
What interventions are being tested in trial NCT01526057?
The interventions under investigation include: PF-05280586 (BIOLOGICAL), Rituxan (BIOLOGICAL), MabThera (BIOLOGICAL).
Who is sponsoring clinical trial NCT01526057?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.